Skip to main content
Evidence Snapshot

Glucagon-like peptide 1 receptor

CHEMBL1784 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1784
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glucagon-like peptide 1 receptor as ChEMBL target CHEMBL1784, mapped to UniProt P43220. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glucagon-like peptide 1 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1784
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43220
Glucagon-like peptide 1 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Glucagon-like peptide 1 receptor matters

As of 2026-09-13

Glucagon-like peptide 1 receptor is reviewed as Glucagon-like peptide 1 receptor (UniProt P43220); Glucagon-like peptide 1 receptor shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.; 15 linked drugs keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 107157 compounds, and 276 assays, with lead potency reaching pChEMBL 11.0.

Disease context
type 2 diabetes mellitus

Glucagon-like peptide 1 receptor shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 15 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALBIGLUTIDE, AVEXITIDE, COTADUTIDE.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALBIGLUTIDE, AVEXITIDE, COTADUTIDE, DANUGLIPRON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 15 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 107157 compounds, and 276 assays for this target. The dominant activity type is EC50. CHEMBL524907 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL524907 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Glucagon-like peptide 1 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43220, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why type 2 diabetes mellitus is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

107157
Total Compounds
276
Total Assays
12
Approved Drugs
IC50: 345.0, KI: 63.0, EC50: 2064.0, KD: 12.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL524907
 11.0 EC50 —
No preferred name
CHEMBL4070096
 11.0 EC50 —
No preferred name
CHEMBL4867885
 11.0 EC50 —
No preferred name
CHEMBL3616760
 11.0 EC50 —
No preferred name
CHEMBL1222096
 11.0 EC50 —

Approved Drugs

Structure Compound First Approval
LIRAGLUTIDE
CHEMBL4084119
 2009
EXENATIDE
CHEMBL414357
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1784